Politiparty
Politiparty
LeaderboardCongressBills

119th Congress Health

H.R. 2821: FDA Modernization Act 3.0

Passed HouseJul 20, 2026

  1. Introduced (completed)Apr 10, 2025
  2. Passed House (completed)Jul 20, 2026
  3. Passed Senate (not reached)
  4. To the President (not reached)
  5. Became law (not reached)

Summary

Introduced in House, Apr 10, 2025

This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug.

The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications.

The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.

Written by the Congressional Research Service, Library of Congress.

Roll calls

0 votes on this bill

No roll call votes have been held on this bill.

Amendments

0 offered

No amendments were offered to this bill.

Cosponsors

41

Bipartisan support.

Who scored on this bill

238 points earned
  1. 1Earl Carter R-GA SponsorDrew cross-party cosponsors, introduced, reached a cosponsor milestone, marked up, reported, passed House6 events+74
  2. 2Nanette Barragán D-CACosponsored; cosponsored bill passed2 events+4
  3. 2Gus Bilirakis R-FLCosponsored; cosponsored bill passed2 events+4
  4. 2Vern Buchanan R-FLCosponsored; cosponsored bill passed2 events+4
  5. 2Ken Calvert R-CACosponsored; cosponsored bill passed2 events+4
See all scorers and every scoring event

Introductions and cosponsorships count toward weekly caps and show no points.

Other bills by Earl Carter

History

  1. Jul 20, 2026Passed the House by voice vote.
  2. Apr 10, 2025Introduced in the House by Earl Carter.
Show the full action history (19 actions)
  1. Jul 21, 2026Received in the Senate.
  2. Jul 20, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H4639)
  3. Jul 20, 2026Considered under suspension of the rules. (consideration: CR H4639-4640)
  4. Jul 20, 2026On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H4639)
  5. Jul 20, 2026Mr. Guthrie moved to suspend the rules and pass the bill.
  6. Jul 20, 2026Considered under suspension of the rules.
  7. Jul 20, 2026DEBATE - The House proceeded with forty minutes of debate on H.R. 2821.
  8. Jul 20, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.
  9. Jul 20, 2026On motion to suspend the rules and pass the bill Agreed to by voice vote.
  10. Jul 20, 2026Motion to reconsider laid on the table Agreed to without objection.
  11. Jun 18, 2026Reported by the Committee on Energy and Commerce. H. Rept. 119-706.
  12. Jun 18, 2026Placed on the Union Calendar, Calendar No. 614.
  13. May 21, 2026Committee Consideration and Mark-up Session Held
  14. May 21, 2026Ordered to be Reported by the Yeas and Nays: 44 - 0.
  15. May 13, 2026Subcommittee Consideration and Mark-up Session Held
  16. May 13, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
  17. Apr 10, 2026Referred to the Subcommittee on Health.
  18. Apr 10, 2025Introduced in House
  19. Apr 10, 2025Referred to the House Committee on Energy and Commerce.